Insider Transactions in Q2 2022 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 31
2022
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,333
+49.21%
|
$0
$0.84 P/Share
|
|
May 02
2022
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
660
-16.24%
|
$7,260
$11.75 P/Share
|
|
May 02
2022
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
697
-24.15%
|
$7,667
$11.75 P/Share
|
|
May 02
2022
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
330
-34.3%
|
$3,630
$11.75 P/Share
|
|
May 02
2022
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,098
-6.02%
|
$12,078
$11.75 P/Share
|
|
Apr 30
2022
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,924
+32.14%
|
-
|
|
Apr 30
2022
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+50.0%
|
-
|
|
Apr 30
2022
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+50.0%
|
-
|
|
Apr 30
2022
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,206
+14.94%
|
-
|